• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Sofinnova

lighthouse in stormy night
Biotech

Gene therapy biotech secures $150M for eye disease candidates

Atsena has raised $150 million to advance its gene therapy designed to reverse or prevent blindness.
Gabrielle Masson Apr 2, 2025 7:30am
Europe Euro European biotech European startup fundraising

Sofinnova closes €165M European biotech acceleration fund

Mar 18, 2025 4:01am
Euros cash money

Sofinnova's €1.2B to fuel up to 60 life sciences companies

Mar 4, 2025 4:56am
bullish sentiment

Why biotechs can benefit from the 'rational' IPO environment

Jan 24, 2025 10:30am
black and white art of eyes

2 eye disease biotechs merge, set sights on FDA approval

Dec 12, 2024 11:05am
IPO initial public offering Wall Street

BioAge eyes $180M from IPO, private placement for obesity trials

Sep 25, 2024 7:55am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings